And part of the devastating impact of these nos is that these companies again doing this for free is going to really reduce the incentive for these companies to address rare diseases. They'll never make a profit on this. They'll never make a profit on it. The genetic therapy for the SanFilippo had the CEO of the company, they took it over from another company whose board of directors said you have to stop producing. (21:43–21:46)
CLAIM
Asserts that companies will not profit from treatments for rare diseases.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
